Share
1,439 Posts.
lightbulb Created with Sketch. 49
clock Created with Sketch.
22/03/17
08:16
Share
Originally posted by Imagine2020
↑
It has been discuss significantly over the last few weeks how long it takes to get a therapeutic drug to market for humans.
But let's not forget about what the company accounced on the 17th November 2014; see below...
Cellmid Limited (ASX:CDY) signed an agreement with Zoetis for the evaluation and option to license one of Cellmid’s anti-midkine antibodies (MK antibody) for therapeutic use in companion animals.
Cellmid’s proprietary MK antibodies have previously been shown to be effective in animal models of a number of diseases. Zoetis has extensive experience in the development and commercialization of animal health products and will evaluate the performance of Cellmid’s MK antibody in their proprietary models with the view to license.
------
The animal health care market is worth billions and the speed to entry is much faster and easier
Imagine what the company would be worth pulling off an animal therapeutic program with Zoetis and a human clinical brain cancer cannenboid program with GW Pharma
Not to mention Evolis and the cash cow it will become in the not to distant future.
My inclination is management is lining all the ducks up!
Be it 1, 2, 5 or 10 years I'll be riding this one out and get paid a premium when a takeover bid arrives
Expand
I just did a little research on Zoetis. They are about to receive EMA approval for a new product called CYTOPOINT which is described as the first monoclonal antibody in veterinary medicine. See the attached link - http://www.ema.europa.eu/ema/index....news_detail_002696.jsp&mid=WC0b01ac058004d5c1
How would one determine if midkine plays any part in this antibody.